Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $87.3 million.

  • Kymera Therapeutics' Shares Outstanding (Weighted Average) rose 1467.87% to $87.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.3 million, marking a year-over-year increase of 1467.87%. This contributed to the annual value of $75.0 million for FY2024, which is 2857.59% up from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' Shares Outstanding (Weighted Average) is $87.3 million, which was up 1467.87% from $80.4 million recorded in Q2 2025.
  • Kymera Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $87.3 million during Q3 2025, with a 5-year trough of $44.6 million in Q1 2021.
  • For the 5-year period, Kymera Therapeutics' Shares Outstanding (Weighted Average) averaged around $61.9 million, with its median value being $58.3 million (2023).
  • In the last 5 years, Kymera Therapeutics' Shares Outstanding (Weighted Average) surged by 218659.43% in 2021 and then skyrocketed by 712.63% in 2023.
  • Quarter analysis of 5 years shows Kymera Therapeutics' Shares Outstanding (Weighted Average) stood at $48.0 million in 2021, then grew by 12.39% to $53.9 million in 2022, then rose by 8.22% to $58.4 million in 2023, then increased by 28.58% to $75.0 million in 2024, then grew by 16.33% to $87.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $87.3 million for Q3 2025, versus $80.4 million for Q2 2025 and $80.1 million for Q1 2025.